- Home
- QNCX vs CUE Comparison
QNCX vs CUE Comparison
Compare QNCX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- CUE
- Stock Information
- Founded
- QNCX 2012
- CUE 2014
- Country
- QNCX United States
- CUE United States
- Employees
- QNCX N/A
- CUE N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- QNCX Health Care
- CUE Health Care
- Exchange
- QNCX Nasdaq
- CUE Nasdaq
- Market Cap
- QNCX 47.7M
- CUE 48.0M
- IPO Year
- QNCX 2019
- CUE 2018
- Fundamental
- Price
- QNCX $2.00
- CUE $0.74
- Analyst Decision
- QNCX Strong Buy
- CUE Strong Buy
- Analyst Count
- QNCX 5
- CUE 3
- Target Price
- QNCX $8.00
- CUE $3.00
- AVG Volume (30 Days)
- QNCX 374.6K
- CUE 323.3K
- Earning Date
- QNCX 08-12-2025
- CUE 08-13-2025
- Dividend Yield
- QNCX N/A
- CUE N/A
- EPS Growth
- QNCX N/A
- CUE N/A
- EPS
- QNCX N/A
- CUE N/A
- Revenue
- QNCX N/A
- CUE $7,991,000.00
- Revenue This Year
- QNCX N/A
- CUE N/A
- Revenue Next Year
- QNCX N/A
- CUE $23.84
- P/E Ratio
- QNCX N/A
- CUE N/A
- Revenue Growth
- QNCX N/A
- CUE 13.83
- 52 Week Low
- QNCX $0.51
- CUE $0.45
- 52 Week High
- QNCX $2.45
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- QNCX 70.90
- CUE 51.10
- Support Level
- QNCX $1.55
- CUE $0.65
- Resistance Level
- QNCX $1.71
- CUE $0.83
- Average True Range (ATR)
- QNCX 0.15
- CUE 0.07
- MACD
- QNCX 0.02
- CUE 0.01
- Stochastic Oscillator
- QNCX 89.09
- CUE 30.43
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.